Italy: G Square solidifies control of G21 with majority stake

G Square Healthcare Private Equity has completed the acquisition of a majority stake in G21, a renowned medtech company operating in Italy. G21 specializes in developing, manufacturing, and distributing cutting-edge equipment and solutions catering to orthopaedic and spine applications, with a particular focus on bone cements, modular spacers, and minimally invasive surgical products for kyphoplasty and vertebroplasty procedures.

Established in 2009, G21 has solidified its presence in Italy, the United States, and on a global scale, providing services to medical professionals and healthcare facilities in more than 55 countries. The company’s rapid growth and commitment to innovation have positioned it as a leader in the industry.

G Square will collaborate closely with G21’s founders, Filippo and Maurizio Foroni, as well as senior advisor Luigi Ferrari, to drive the company’s advancement into its next chapter. The partnership aims to propel international expansion, particularly within the US market, enhance the global distribution network, and foster continued research and development initiatives.

Dr. Laurent Ganem, G Square’s founder and CEO, expressed admiration for G21’s accomplishments and identified immense potential for future growth within the company. The details of the transaction, including financial terms, were not disclosed to the public.

The increasing global population, combined with demographic shifts towards an aging society, has led to heightened demand for orthopaedic treatments, such as hip and knee replacements. Lifestyle factors, including obesity and sedentary behaviors, further contribute to the need for joint-related interventions even among younger individuals. Advances in surgical techniques have not only improved patient outcomes but also streamlined procedures, reducing costs and recovery times. Consequently, the orthopedic reconstruction market is witnessing substantial growth.

Recognizing the lucrative opportunities within the sector, various private equity firms have been actively investing in medtech companies. Astorg Partners’ acquisition of Demetra Holding, a prominent player in bone cement and biomaterials, in August 2021 exemplifies this trend. Novo Holdings’ recent investment in UK-based Biocomposites underscores the industry’s attractiveness to investors seeking to capitalize on its expansion potential.

The medtech landscape continues to evolve rapidly, driven by technological innovation and the growing healthcare needs of an aging population. G Square’s strategic partnership with G21 signifies a commitment to fostering innovation, enhancing global reach, and delivering advanced healthcare solutions to meet the evolving demands of medical professionals worldwide.